Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy-Reference-Cited by-同舟云学术

Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy

Published:2021-11 Issue: Volume:73 Page:103636
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Gadani Sachin P.^ORCID,Reyes-Mantilla Maria,Jank Larissa,Harris Samantha,Douglas Morgan,Smith Matthew D.,Calabresi Peter A.,Mowry Ellen M.,Fitzgerald Kathryn C.^ORCID,Bhargava Pavan^ORCID

Funder

National Institute of Mental Health

National Multiple Sclerosis Society

Amylin Pharmaceuticals

Genentech

EMD Serono

National Institutes of Health

Johns Hopkins University School of Medicine

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference26 articles.

1. Multiple sclerosis management during the COVID-19 pandemic;Moss;Mult Scler J,2020

2. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis;Sormani;Ann Neurol,2021

3. Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases;Fitzgerald;Clin Infect Dis,2021

4. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting;Dagan;N Engl J Med,2021

5. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine;Polack;N Engl J Med,2020

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 Vaccination Responses in Anti-CD20-Treated Progressive Multiple Sclerosis Patients Show Immunosenescence in Antigen-Specific B and T Cells;Vaccines;2024-08-17

2. Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants;Science Bulletin;2024-08

3. De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate;Advances in Therapy;2024-06-11

4. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab;JAMA Network Open;2024-04-12

5. Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients;Nature Communications;2024-03-29